Gen-Probe Begins Clinical Study of Test to Assess Prostate Cancer Risk

Gen-Probe Incorporated announced that the company has begun a clinical trial intended to secure U.S. regulatory approval of its Progensa PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Los Angeles Business